Dimensional Fund Advisors LP Buys 56,336 Shares of DaVita Inc. $DVA

Dimensional Fund Advisors LP boosted its stake in DaVita Inc. (NYSE:DVA) by 5.2% in the first quarter, Holdings Channel reports. The firm owned 1,145,436 shares of the company’s stock after purchasing an additional 56,336 shares during the quarter. Dimensional Fund Advisors LP’s holdings in DaVita were worth $176,037,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of DVA. Root Financial Partners LLC increased its holdings in DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock valued at $29,000 after buying an additional 105 shares during the period. Caitlin John LLC acquired a new position in shares of DaVita in the 4th quarter valued at approximately $34,000. Sankala Group LLC bought a new stake in shares of DaVita during the 4th quarter worth approximately $39,000. Canada Pension Plan Investment Board acquired a new stake in shares of DaVita during the 2nd quarter worth approximately $43,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of DaVita during the 4th quarter worth approximately $45,000. Institutional investors own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other DaVita news, CFO Joel Ackerman sold 51,471 shares of the stock in a transaction dated Thursday, May 7th. The stock was sold at an average price of $192.10, for a total value of $9,887,579.10. Following the completion of the transaction, the chief financial officer directly owned 132,434 shares in the company, valued at approximately $25,440,571.40. This trade represents a 27.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Kathleen Alyce Waters sold 15,405 shares of DaVita stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider directly owned 109,194 shares in the company, valued at $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 1.90% of the stock is owned by corporate insiders.

DaVita Price Performance

Shares of DaVita stock opened at $235.46 on Friday. The company’s 50 day moving average price is $213.62 and its two-hundred day moving average price is $168.71. The firm has a market capitalization of $15.12 billion, a P/E ratio of 21.84, a P/E/G ratio of 0.77 and a beta of 0.88. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $239.64.

DaVita (NYSE:DVA) last announced its quarterly earnings results on Tuesday, May 5th. The company reported $2.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.33 by $0.54. DaVita had a net margin of 5.65% and a negative return on equity of 270.37%. The company had revenue of $3.42 billion during the quarter, compared to the consensus estimate of $3.36 billion. During the same period in the prior year, the business earned $2.00 earnings per share. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. On average, analysts expect that DaVita Inc. will post 15.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on DVA. Truist Financial upped their target price on DaVita from $205.00 to $250.00 and gave the stock a “hold” rating in a research note on Tuesday, July 14th. UBS Group lifted their price target on DaVita from $235.00 to $270.00 and gave the company a “buy” rating in a research note on Friday, July 10th. Weiss Ratings reissued a “hold (c+)” rating on shares of DaVita in a report on Monday, June 8th. Zacks Research downgraded DaVita from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Finally, Barclays raised their price objective on DaVita from $194.00 to $218.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 8th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $216.50.

About DaVita

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.